Hypermethylation of p16(ink4a) and p15(ink4b) genes as a marker of disease in the follow-up of non-Hodgkin's lymphomas

British Journal of Haematology

Volumn 109, Issue 1, 2000, Pages 97-103

  Martinez Delgado, Beatriz ^a   Richart, Alberto ^a   García, Maria Jose ^a   Robledo, Mercedes ^a   Osorio, Ana ^a   Cebrian, Arancha ^a   Rivas, Carmen ^a   Benitez, Javier ^a  

^a Hospital UniversitarioFundación Jiménez Díaz   (Spain)

Author keywords

Follow up; Lymphoma; Methylation; p15; p16

Indexed keywords

ALKYLATING AGENT; ANTIBIOTIC AGENT; ANTIINFECTIVE AGENT; ANTIMETABOLITE; BLEOMYCIN; CYCLOPHOSPHAMIDE; CYTOTOXIC AGENT; DOXORUBICIN; METHOTREXATE; PREDNISONE; STEROID; VINCRISTINE; CARRIER PROTEIN; CDKN2B PROTEIN, HUMAN; CELL CYCLE PROTEIN; CYCLIN DEPENDENT KINASE INHIBITOR 2B; PROTEIN P16INK4A; TUMOR SUPPRESSOR PROTEIN;

ADOLESCENT; ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER RECURRENCE; CANCER REGRESSION; CELL POPULATION; CHILD; CLINICAL ARTICLE; FEMALE; FOLLOW UP; GENE REARRANGEMENT; HUMAN; MALE; METHYLATION; MONITORING; NONHODGKIN LYMPHOMA; PATIENT MONITORING; POLYMERASE CHAIN REACTION; PRESCHOOL CHILD; PRIORITY JOURNAL; SCHOOL CHILD; DNA METHYLATION; GENETIC MARKER; GENETICS; IMMUNOGLOBULIN GENE; MIDDLE AGED; TUMOR SUPPRESSOR GENE;

ADULT; AGED; CARRIER PROTEINS; CELL CYCLE PROTEINS; CYCLIN-DEPENDENT KINASE INHIBITOR P15; CYCLIN-DEPENDENT KINASE INHIBITOR P16; DNA METHYLATION; FEMALE; FOLLOW-UP STUDIES; GENE REARRANGEMENT; GENE REARRANGEMENT, GAMMA-CHAIN T-CELL ANTIGEN RECEPTOR; GENES, IMMUNOGLOBULIN; GENES, P16; GENETIC MARKERS; HUMANS; LYMPHOMA, NON-HODGKIN; MALE; MIDDLE AGED; TUMOR SUPPRESSOR PROTEINS;

EID: 0034171059     PISSN: 00071048     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2141.2000.01991.x     Document Type: Article

References (26)

1. Belinsky, S.A., Nikula, K.J., Palmisano, W.A., Michels, R., Saccomanno, G., Gabrielson, E., Baylin, S.B. & Herman, J.G. (1998) Aberrant methylation of p16 (ink4a) is an early event in lung cancer and a potential biomarker for early diagnosis. Proceedings of the National Academy of Sciences of the United States of America, 95, 11891-11896.
2. Deane, M. & Norton, J.D. (1990) Detection of immunoglobulin gene rearrangement in B lymphoid malignancies by polymerase chain reaction gene amplification. British Journal of Haematology, 74, 251-256.
3. Diss, T.C., Peng, H., Wotherspoon, A.C., Isaacson, P.G. & Pan, L. (1993) Detection of monoclonality in low-grade B-cell lymphomas using the polymerase chain reaction is dependent on primer selection and lymphoma type. Journal of Pathology, 169, 291-295.
4. Drexler, H.G. (1998) Review of alterations of the cyclin-dependent kinase inhibitor INK4 family genes p15, p16, p18 and p19 in human leukemia-lymphoma cells. Leukemia, 12, 845-859.
5. Hangaishi, A., Ogawa, S., Imamura, N., Miyawaki, S., Miura, Y., Uike, N., Shimazaki, C., Emi, N., Takeyama, K., Hirosawa, S., Kamada, N., Kobayashi, Y., Takemoto, Y., Kitani, T., Toyama, K., Ohtake, S., Yazaki, Y., Ueda, R. & Hirai, H. (1996) Inactivation of multiple tumor suppressor genes involved in negative regulation of the cell cycle, MTS1/p16ink4a/CDKN2, MTS2/p15ink4b/ CDKN2B, p53, and Rb genes in primary lymphoid malignancies. Blood, 87, 4949-4958.
6. Hannon, G.J. & Beach, D. (1994) P15ink4b is a potential effector of TGF-B induced cell cycle arrest. Nature, 371, 257.
7. Harris, N., Jaffe, E.S., Stein, H., Banks, P.M., Chan, J.K.C., Cleary, M.L., Delsol, G., De Wolf-Peeters, Falini, B., Gatter, K.C., Grogan, T.M., Issacson, P., Knowles, D.M., Mason, D., Muller-Hermelink, H.K., Pileri, S.A., Piris, M.A., Ralfkiaer, E. & Warnke, R.A. (1994) Revised European-American classification of lymphoid neoplasms: a proposal from the international lymphoma study group. Blood, 84, 1361-1392.
8. Herman, J.G., Jen, J., Merlo, A. & Baylin, S.B. (1996a) Hypermethylation-associated inactivation indicates a tumor suppressor role for p15ink4B. Cancer Research, 56, 722-727.
9. Herman, J.G., Graff, J.R., Myöhänen, S., Nelkin, B.D. & Baylin, S.B. (1996b) Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. Proceedings of the National Academy of Sciences of the United States of America, 93, 9821-9826.
10. Herman, J.G., Civin, C.I., Issa, J.P.J., Collector, M.I., Sharkis, S.J. & Baylin, S.B. (1997) Distinct patterns of inactivation of p15ink4b and p16ink4a characterize the major types of hematological malignancies. Cancer Research, 57, 837-841.
11. Issa, J.P.J., Zehnbauer, B.A., Civin, C.I., Collector, M.I., Sharkis, S.J., Davidson, N.E., Kaufmann, S.H. & Baylin, S.B. (1996) The estrogen receptor CpG island is methylated in most hematopoietic neoplasms. Cancer Research, 56, 973-977.
12. Jen, J., Harper, W., Bigner, S.H., Bigner, D.D., Papadopoulos, N., Markowitz, S., Wilson, J.K.V., Kinzler, K.W. & Vogelstein, B. (1994) Deletions of p16 and p15 genes in brain tumors. Cancer Research, 54, 6353.
13. Maloney, K.W., McGavran, L., Odom, L.F. & Hunger, S.P. (1999) Acquisition of p16 (ink4a) and p15 (ink4b) gene abnormalities between initial diagnosis and relapse in children with acute lymphoblastic leukemia. Blood, 93, 2380-2385.
14. Martinez-Delgado, B., Fernandez-Piqueras, J., Garcia, M.J., Arranz, E., Rivas, C. & Robledo, Benitez, J. (1997) Hypermethylation of 5′ CpG island of p16 is a frequent event in non-Hodgkin's lymphomas. Leukemia, 11, 425-428.
15. McCarthy, K.P. (1997) Molecular diagnosis of lymphomas and associated diseases. Cancer Metabolism Review, 16, 109-125.
16. Merlo, A., Herman, J.G., Mao, L., Lee, D.J., Gabrielson, E., Burger, P.C., Baylin, S.B. & Sidransky, D. (1995) 5′CpG island methylation is associated with transcriptional silencing of the tumor suppressor p16/CDKN2/MTS1 in human cancers. Nature Medicine, 1, 686-692.
17. Nyce, J. (1989) Drug-induced DNA hypermethylation and drug resistance in human tumors. Cancer Research, 49, 5829-5836.
18. Otsuki, T., Clark, H.M., Wellmann, A., Jaffe, E.S. & Raffeld, M. (1995) Involvement of CDKN2 (p16ink4A/MTS1) and p15ink4B/MTS2 in human leukemias and lymphomas. Cancer Research, 55, 1436.
19. Pinyol, M., Cobo, F., Bea, S., Jares, P., Nayach, I., Fernandez, P.L., Monserrat, E., Cardesa, A. & Campo, E. (1998) P16ink4a gene inactivation by deletions, mutations and hypermethylation is associated with transformed and aggressive variants of non Hodgkin's lymphomas. Blood, 91, 2977-2984.
20. Quesnel, B., Guillerm, C., Vereecque, R., Wattel, E., Preudhomme, C., Bauters, F., Vanrumbeke, M. & Fenaux, P. (1998) Methylation of the p15ink4b gene in myelodysplastic syndromes is frequent and acquired during disease progression. Blood, 91, 2985-2990.
21. Serrano, M., Hannon, G.J. & Beach, D. (1993) A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4. Nature, 366, 704-707.
22. Stranks, G., Height, S.E., Mitchell, P., Jadayel, D., De Yuille, M.A.R., Lord, C., Clutterbuck, R.D., Treleaven, J.G., Powles, R.L., Nacheva, E., Oscier, D.G., Karpas, A., Lenoir, G.M., Smith, S.D., Millar, J.L., Catovsky, D. & Dyer, M.J.S. (1995) Deletions and rearrangement of CDKN2 in lymphoid malignancy Blood, 85, 893-901.
23. Trainor, K.J., Brisco, M.J., Story, C.J. & Morley, A.A. (1990) Monoclonality in B-lymphoproliferative disorders detected at the DNA level. Blood, 75, 2220-2222.
24. Trainor, J.K., Brisco, M.J., Wan, J.H., Nech, S., Grist, S. & Morley, A.A. (1991) Gene rearrangement in B-and T-lymphoproliferative disease detected by the polymerase chain reaction. Blood, 78, 192-196.
25. Uchida, T., Watanabe, T., Kiroshita, T., Murate, T., Saito, H. & Hotta, T. (1995) Mutational analysis of the CDKN2 (MTS1/ink4a) gene in primary B-cell lymphomas. Blood, 86, 2724-2731.
26. Villuendas, R., Sanchez-Beato, M., Martinez, J.C., Saez, A.I., Martinez-Delgado, B., Garcia, J.F., Mateo, M.S., Benitez, J., Martinez, P. & Piris, M.A. (1998) Loss of p16/INK4A protein expression in non Hodgkin's lymphomas is a frequent finding associated with tumor progression. American Journal of Pathology, 153, 887-897.